MARKET INSIGHTS

The Global Metamizole API market size was valued at USD 159 million in 2025. The market is projected to decline to USD 144 million by 2034, exhibiting a compound annual growth rate (CAGR) of -1.6% during the forecast period from 2026 to 2034.

Metamizole API, also known as Analgin API, is the pure active pharmaceutical ingredient used as a non-opioid analgesic and antipyretic for the treatment of severe pain and fever. This compound serves as the critical raw material for formulators who manufacture various finished dosage forms, including injections for intravenous or intramuscular use, oral tablets, syrups, and rectal suppositories. It is particularly vital in medical settings where rapid relief from acute pain is required. In terms of production volume, the market produced approximately 19.31 thousand metric tons (K MT) in 2025, against a global production capacity estimated at around 26 K MT.

The market’s projected contraction is primarily due to its restricted legal status in several major markets, such as the United States, Japan, and several European countries, because of associated safety concerns like agranulocytosis. However, demand is expected to persist, supported by continued clinical use in regions where it remains approved, including parts of Latin America, Asia, and specific European nations. The industrial chain for Metamizole API is upstreamed by basic petrochemicals and inorganic reagents, while downstream, manufacturers convert the API into final pharmaceutical products for hospital and retail distribution in permissible markets.

Metamizole API Market – View in Detailed Research Report

🔟 1. Xinhua Pharmaceutical Company Limited

Headquarters: Shanghai, China
Key Offering: High‑purity Metamizole API (99%+), injectable formulations

Xinhua Pharmaceutical is a leading global producer of Metamizole API, leveraging extensive chemical manufacturing infrastructure and a robust supply chain. The company focuses on high‑purity grades to meet stringent pharmacopoeial standards, particularly for injectable products used in acute pain management.

Sustainability & Growth Initiatives:

• Investing in process‑optimized synthesis routes to improve yield and reduce impurities.
• Expanding production capacity to meet growing demand in Latin America and Asia.
• Strengthening GMP compliance to support regulatory approvals in key markets.

9️⃣ 2. Moehs Group

Headquarters: Madrid, Spain
Key Offering: 99%+ purity API, injectable and oral dosage forms

The Moehs Group, with deep regulatory expertise in the European market, supplies high‑quality Metamizole API to formulators in countries where the drug remains approved. Its focus on quality and regulatory compliance has positioned it as a trusted partner for European manufacturers.

Sustainability & Growth Initiatives:

• Enhancing supply chain resilience through local sourcing of raw materials.
• Investing in advanced purification technologies to maintain 99%+ purity.
• Collaborating with EU regulatory bodies to streamline approval processes.

8️⃣ 3. Wuyao Pharmaceutical Co., Ltd

Headquarters: Guangzhou, China
Key Offering: Cost‑effective Metamizole API, bulk and specialty grades

Wuyao Pharmaceutical specializes in high‑yield, cost‑effective production of Metamizole API, catering to both domestic and international formulators. The company’s efficient manufacturing processes help keep prices competitive while maintaining quality.

Sustainability & Growth Initiatives:

• Implementing lean manufacturing to reduce waste and lower production costs.
• Expanding into new regional markets through strategic partnerships.
• Upgrading quality control labs to meet evolving regulatory standards.

7️⃣ 4. Jiheng Pharmaceutical Co., Ltd

Headquarters: Shenzhen, China
Key Offering: High‑purity API for injectable formulations

Jiheng Pharmaceutical is renowned for its stringent quality controls and focus on injectable‑grade Metamizole API. The company serves a broad network of formulators across Asia and Latin America.

Sustainability & Growth Initiatives:

• Investing in advanced purification equipment to ensure 99%+ purity.
• Developing regional distribution centers to reduce lead times.
• Collaborating with research institutions to improve synthesis efficiency.

6️⃣ 5. Haisen Pharma

Headquarters: Nanjing, China
Key Offering: Bulk Metamizole API, cost‑effective production

Haisen Pharma focuses on large‑scale, cost‑effective production of Metamizole API, serving both domestic and export markets. The company’s emphasis on process optimization helps it maintain competitive pricing.

Sustainability & Growth Initiatives:

• Adopting green chemistry practices to reduce environmental impact.
• Enhancing raw material sourcing to secure supply stability.
• Expanding capacity in response to rising demand in emerging economies.

5️⃣ 6. Hachidai Pharmaceutical Co Ltd

Headquarters: Osaka, Japan
Key Offering: High‑purity API for both human and veterinary use

Hachidai Pharmaceutical supplies high‑purity Metamizole API to Japanese formulators, with a focus on meeting strict domestic safety and quality standards. The company also explores niche veterinary applications where regulatory restrictions are less stringent.

Sustainability & Growth Initiatives:

• Investing in precision synthesis technologies to minimize impurities.
• Strengthening partnerships with local raw material suppliers.
• Exploring opportunities in emerging markets with relaxed regulatory frameworks.

4️⃣ 7. Vani Pharma Labs Limited

Headquarters: Mumbai, India
Key Offering: Cost‑effective Metamizole API for injectable and oral dosage forms

Vani Pharma Labs focuses on delivering affordable Metamizole API to Indian formulators and regional partners. The company’s emphasis on process efficiency helps keep production costs low while maintaining quality.

Sustainability & Growth Initiatives:

• Implementing process‑optimized synthesis routes to boost yields.
• Expanding domestic manufacturing footprint to reduce import dependency.
• Engaging with government initiatives to promote local API production.

3️⃣ 8. Huadong Medicine (Xi’an) Bohua Pharmaceutical Co., Ltd.

Headquarters: Xi’an, China
Key Offering: High‑purity API for injectable formulations

Huadong Medicine specializes in producing high‑purity Metamizole API for injectable use, catering to formulators in China and neighboring regions. The company’s rigorous quality control ensures compliance with international GMP standards.

Sustainability & Growth Initiatives:

• Upgrading production facilities to incorporate advanced purification systems.
• Strengthening quality management systems to meet global regulatory requirements.
• Expanding export capacity to meet growing demand in Latin America.

2️⃣ 9. Chemcopia Ingredients Pvt Ltd

Headquarters: Bangalore, India
Key Offering: Bulk and specialty Metamizole API

Chemcopia Ingredients focuses on producing both bulk and specialty grades of Metamizole API, targeting domestic formulators and export markets. The company leverages its expertise in process optimization to maintain high purity and cost efficiency.

Sustainability & Growth Initiatives:

• Investing in process‑controlled synthesis routes to reduce impurities.
• Enhancing raw material sourcing to secure supply stability.
• Collaborating with regional partners to expand market reach.

1️⃣ 10. SinoPharma

Headquarters: Beijing, China
Key Offering: High‑purity Metamizole API for injectable and oral dosage forms

SinoPharma is a rapidly growing manufacturer of Metamizole API, emphasizing high purity and stringent quality controls. The company serves a growing base of formulators in Asia and Latin America.

Sustainability & Growth Initiatives:

• Adopting green chemistry practices to minimize environmental impact.
• Expanding production capacity to meet rising demand in emerging markets.
• Strengthening GMP compliance to support regulatory approvals worldwide.

Download FREE Sample Report: Metamizole API Market – View in Detailed Research Report

Get Full Report Here: Metamizole API Market – View in Detailed Research Report

🌍 Outlook: The Future of Metamizole API Market

The Metamizole API market is experiencing a slight contraction, with a projected decline from USD 159 million in 2025 to USD 144 million by 2034, reflecting a CAGR of -1.6%. This trend is driven by the compound’s restricted legal status in major markets such as the United States, United Kingdom, Japan, and several European countries due to safety concerns like agranulocytosis. Demand remains concentrated in regions where the drug is approved, including Latin America, parts of Europe (Germany, Spain), Russia, and parts of Asia. The market’s stability is underpinned by continued clinical reliance on Metamizole for severe pain and high fever management, particularly in hospital settings where rapid onset of action is valued.

📈 Key Trends Shaping the Market:

• Growing emphasis on high‑purity grades (99%+), driven by stricter impurity control requirements.
• Continued demand for injectable formulations, especially Analgin Injection, due to its critical role in acute care.
• Shift towards high‑yield, impurity‑controlled synthesis routes to improve cost efficiency and meet regulatory standards.
• Expansion of local manufacturing hubs in Asia to reduce import dependence and enhance supply chain resilience.
• Increasing focus on strategic API manufacturing hubs to serve regional markets and pre‑qualified procurement agencies.